Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | APAF1 | O14727 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Soulattrolide SCHEMBL2040583 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CA12CA9MAPK1CA1 | |
| Soulattrolide SCHEMBL2038701 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CA12CA9MAPK1CA1 | |
| Soulattrolide SCHEMBL8698180 | 1.00 | ALDH1A1 (0.67) | ALDH1A1CA12CA9MAPK1CA1 | |
| SCHEMBL8698429 | 0.83 | ALDH1A1 (0.45) | ALDH1A1CA12CA9MAPK1CA1 | |
| SCHEMBL8702867 | 0.83 | ALDH1A1 (0.45) | ALDH1A1CA12CA9MAPK1CA1 | |
| SCHEMBL8702637 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CA12CA9MAPK1CA1 | |
| SCHEMBL29519060 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CA12CA9MAPK1CA1 | |
| (-)-Calanolide A SCHEMBL8927754 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CA12CA9MAPK1CA1 | |
| Calanolide A SCHEMBL140017 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CA12CA9MAPK1CA1 | |
| Costatolide SCHEMBL8927756 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CA12CA9MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20230200385-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4188090-A2 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | Impello Biosciences, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11638427-B2 | Methods and compositions for altering secondary metabolites in plants | IMPELLO BIOSCIENCES, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220079150-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022026613-A2 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-6774141-B1 | INHIBIT REPLICATION OF RETROVIRUSES SUCH AS LYMPHADENOPATHY ASSOCIATED-, HUMAN IMMUNODEFICIENCY, AND HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUSES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-08-10 | — | — | US | disclosed |
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | disclosed |
| US-20020086898-A1 | Calanolide and related antiviral compounds, compositions, and uses thereof | BOYD MICHAEL R (US) | 2002-07-04 | — | — | US | disclosed |
| EP-0633887-B1 | CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | US HEALTH (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5591770-A | TREATING HUMAN T-CELL LYMPHOMA/LEUKEMIA INFECTIONS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996026934-A1 | SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1996-09-06 | — | — | WO | disclosed |
| EP-0699202-A1 | CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0674643-A1 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0674643-A4 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-08-08 | — | — | EP | disclosed |
| EP-0633887-A1 | CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-18 | — | — | EP | disclosed |
| CN-1096786-A | Be used as the coumarin derivatives of retroviral inhibitors | SMITHKLINE BEECHAM CORP (US) | 1994-12-28 | — | — | CN | disclosed |
| WO-1994028000-A1 | CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994014789-A1 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1993020082-A1 | CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079150-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | ALDH1A1 4108/4885CA12 2899/4885CA9 2263/4885 |
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | ALDH1A1 4108/4885CA12 2899/4885CA9 2263/4885 |
| US-11638427-B2 | Methods and compositions for altering secondary metabolites in plants | ERG28, AHCY, BROX | ALDH1A1 4108/4885CA12 2899/4885CA9 2263/4885 |
| US-20020086898-A1 | Calanolide and related antiviral compounds, compositions, and uses thereof | ZC3HAV1, RPL35, ZC3HAV1L | ALDH1A1 4177/4885CA12 3103/4885CA9 2188/4885 |
| US-20230200385-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | ALDH1A1 4108/4885CA12 2899/4885CA9 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.